Latest news on margetuximab

Margetuximab (Margetuximab) is an innovative antibody drug that has attracted attention in the field of HER2 targeted therapy in recent years. As the demand for treatment of HER2 -positive breast cancer and other related tumors continues to grow, this drug has gradually become an international research hotspot due to its unique antibody engineering advantages and stronger immune activation ability. Regarding its approval status, magituximab is currently approved in the United States and is mainly used for patients with HER2 positive metastatic breast cancer whose disease has progressed after multiple lines of treatment. In addition, Europe, Japan and other regions are still in varying degrees of evaluation or research stages, and official marketing approval results have not yet been announced. That is to say, currently The United States is the main market that has clearly approved margetuximab, while most other countries are in the process of review, clinical trials or preparation for marketing.

1. Drug introduction: HER2 targeted antibody upgraded version based on antibody engineering

Margetuximab is a Fc engineered monoclonal antibody that specifically targets the human epidermal growth factor receptor 2 (HER2). HER2 As a tumor biomarker, it is overexpressed in a variety of highly invasive tumors such as breast cancer and gastroesophageal cancer. Compared with traditional HER2 antibodies, margituximab is not a simple "structural replacement", but is precisely engineered in the Fc fragment, introducing 5 amino acid substitutions to enhance the affinity with the activating Fc γ receptor CD16A while reducing the affinity with the inhibitory The binding of Fcγ receptor CD32B enables it to have stronger immune activation and tumor cell killing capabilities.

This engineering design allows margetuximab to have two key functions: one is to maintain the antibody's precise recognition of the HER2 epitope, and its Fab structure is similar to trastuzumab; the other is to further strengthen the immune system's clearance of tumor cells by enhancing NK antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells and macrophages. This "dual-pathway mechanism" is also the reason why it is considered representative in the field of engineered antibodies.

2. Unique mechanism of action: immune-enhancing antibodies targeting HER2

The Fab region of margetuximab directly binds HER2’s extracellular domain blocks signaling pathways and inhibits tumor growth. Its biggest feature is the immune response amplification effect brought about by Fc engineering.

The modified Fc can more effectively attract NK cells expressing CD16A and reduce the inhibitory reaction with CD32B , making the entire immune activation pathway clearer and more effective. For patients who carry a specific Fcγ receptor genotype and have a weak response to traditional anti- HER2 antibodies, this mechanism is expected to improve their immune response and is an important innovative direction in the current HER2 targeted therapy field.

This engineering method is regarded overseas as one of the key technologies to overcome the limitations of traditional HER2 antibodies, and also allows margetuximab to show potential value in a widely treated patient group.

3. Treatment indications: HER2 positive metastatic breast cancer that has received multiple lines of treatment

In the United States, the main indication for margetuximab is HER2 positive metastatic breast cancer, especially in patients who have received more than two HER2 targeted drugs and still have disease progression. Its research and development goal is to provide a treatment method that further optimizes immune clearance based on previous anti- HER2 antibody treatment.

Overseas clinical studies have shown that compared with standard anti- HER2 antibodies, margetuximab has better performance in immune-dependent killing, so it has gained space for use in metastatic HER2-positive breast cancer. At the same time, its potential is also being used in the research of HER2-expressing solid tumors such as gastroesophageal adenocarcinoma, expanding the possibility of future indication layout.

References: https://www.margenza.com/